Literature DB >> 20486891

A prospective study of hearing preservation in untreated vestibular schwannomas.

Michael E Sughrue1, Ari J Kane, Rajwant Kaur, Jeffrey J Barry, Martin J Rutkowski, Lawrence H Pitts, Steven W Cheung, Andrew T Parsa.   

Abstract

OBJECT: The authors previously published a systematic review of the English language literature regarding the natural history of untreated vestibular schwannomas (VSs). This analysis found that the best predictor of future hearing loss was tumor growth > 2.5 mm/year on serial imaging, a factor that doubled the rate of hearing loss. In this paper the authors present an analysis of prospectively collected outcomes in patients with untreated VS from their institution that confirms their previous findings.
METHODS: Clinical, radiographic, and audiometric data for all patients evaluated for VS at the authors' institution over a 22-year period were prospectively collected in a database. All patients in this database who had serviceable hearing (American Academy of Otolaryngology-Head and Neck Surgery Grade A or B) on initial presentation were selected, and underwent serial observation. Magnetic resonance imaging and audiometric data were analyzed, and the time from presentation until hearing loss was analyzed using Kaplan-Meier analysis.
RESULTS: Fifty-nine patients with VS who initially presented with serviceable hearing were treated conservatively over this period. Consistent with the authors' previous findings, patients with a tumor growth rate > 2.5 mm/year at any point during follow-up lost their hearing at a much faster rate than those who had slower growing tumors. The median time to hearing loss was 7.0 years in those patients with tumor growth rate > 2.5 mm/year compared to 14.8 years in the other patients (p < 0.0001). The estimated median time to hearing loss in the 3 initial tumor size groups was 11.6 years in the intracanalicular group, 10.3 years in the group with 0.1-1 cm extension into the CPA cistern, and 9.3 years in the group with > 1 cm extension into the CPA cistern (p value nonsignificant). Initial tumor size, age at diagnosis, and neurofibromatosis Type 2 status did not affect the time to loss of serviceable hearing. Interestingly, many patients who were followed up for more than a decade eventually lost their hearing, regardless of whether the tumor displayed any documented interval growth.
CONCLUSION: The authors confirmed the findings of their systematic review of the literature using a prospectively followed group of patients with untreated VS. Collectively, these data suggest that the expectation for more rapid hearing loss should be communicated to patients, and the decision for surgical or other intervention should be made in the context of the known risk of continued observation of fast growing tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20486891     DOI: 10.3171/2010.4.JNS091962

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Hypofractionated stereotactic radiotherapy of acoustic neuroma: volume changes and hearing results after 89-month median follow-up.

Authors:  Manfred Kranzinger; Franz Zehentmayr; Gerd Fastner; Gerhard Oberascher; Florian Merz; Olaf Nairz; Hassan Rahim; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

2.  Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Authors:  Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

3.  Gamma Knife Radiosurgery for Large Vestibular Schwannoma More Than 10 cm 3 : A Single-Center Indian Study.

Authors:  Ujwal Yeole; A R Prabhuraj; Arimappamagan Arivazhagan; K V L Narasingarao; Vikas Vazhayil; Dhananjaya Bhat; Dwarakanath Srinivas; Bhanumathi Govindswamy; Somanna Sampath
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-23

4.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

5.  EAONO position statement on Vestibular Schwannoma: Imaging Assessment Question: How should growth of Vestibular Schwannoma be defined?

Authors:  Romain Kania; Benjamin Vérillaud; Domitille Camous; Charlotte Hautefort; Thomas Somers; Jérôme Waterval; Sébastien Froelich; Philippe Herman
Journal:  J Int Adv Otol       Date:  2018-04       Impact factor: 1.017

6.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

7.  Long-Term Hearing Outcomes Following Stereotactic Radiosurgery in Vestibular Schwannoma Patients-A Retrospective Cohort Study.

Authors:  Peter L Santa Maria; Yangyang Shi; Richard K Gurgel; C Eduardo Corrales; Scott G Soltys; Chloe Santa Maria; Kevin Murray; Steven D Chang; Nikolas H Blevins; Iris C Gibbs; Robert K Jackler
Journal:  Neurosurgery       Date:  2019-10-01       Impact factor: 4.654

8.  Initial Observation among Patients with Vestibular Schwannoma.

Authors:  Henry Ruiz-Garcia; Jennifer Peterson; Janet Leon; Timothy Malouff; Laura Vallow; Larry Lundy; Kaisorn L Chaichana; Prasanna Vibhute; Daniel M Trifiletti
Journal:  J Neurol Surg B Skull Base       Date:  2020-01-24

9.  CXCR4: A new player in vestibular schwannoma pathogenesis.

Authors:  Maria Breun; Alexandra Schwerdtfeger; Donato Daniel Martellotta; Almuth F Kessler; Jose M Perez; Camelia M Monoranu; Ralf-Ingo Ernestus; Cordula Matthies; Mario Löhr; Carsten Hagemann
Journal:  Oncotarget       Date:  2018-01-10

10.  ADAM9: A novel player in vestibular schwannoma pathogenesis.

Authors:  Maria Breun; Alexandra Schwerdtfeger; Donato Daniel Martellotta; Almuth F Kessler; Camelia M Monoranu; Cordula Matthies; Mario Löhr; Carsten Hagemann
Journal:  Oncol Lett       Date:  2020-01-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.